0:00 Welcome to Onco Life Center Podcast. 0:02 Imagine sitting in a clinical office. 0:04 You know, a doctor looks you in the eye, uh, tells you that you have cancer, and then tells you their master plan is to, well, do absolutely nothing. 0:13 It's completely counterintuitive to everything we're taught to feel about that word. 0:18 Yeah. 0:18 I mean, no surgery, no radiation, just go home and wait. 0:23 It sounds terrifying, like you are being asked to willingly ignore a literal threat to your life. 0:29 Aaron Powell And for generations, the instinct of both the doctor and the patient upon hearing that word was immediate total eradication. 0:37 Uh sort of a search and destroy mission. 0:40 You find it, you cut it out, or you radiate it as aggressively as possible. 0:45 Right. 0:46 But decades of outcome data regarding very specific types of prostate cancer have basically forced the medical community to step back and completely re-evaluate that reflex. 0:55 We realized that uh our treatments were sometimes causing more long-term harm than the disease itself. 1:02 Aaron Powell And I want to clarify our mission for this deep dive immediately. 1:06 We are looking at a pathway for patients who already have a confirmed diagnosis. 1:10 So this is not a discussion about general screening or, you know, your annual physical. 1:15 Aaron Powell No, we are talking about the critical, really heavy decisions made after the biopsy results are already in. 1:21 And the cancer is officially on paper. 1:24 Exactly. 1:25 For men on active surveillance, the whole protocol fundamentally changes the relationship a person has with their own biology. 1:31 Aaron Powell It certainly does. 1:33 Aaron Ross Powell We are shifting from an acute crisis intervention model to uh well to a chronic management model. 1:40 We're asking patients to override their most primal survival instincts, which you know scream at them to remove the threat. 1:46 Aaron Powell And instead trust a highly disciplined system of observation. 1:50 To make this system crystal clear for you listening, I want to introduce the only analogy we really need today, which is the detective stakeout. 1:59 Aaron Powell I think that framing is perfect for this. 2:02 Think of a prostate cancer diagnosis like the police discovering a suspicious person operating inside a building. 2:08 Now, the old school search and destroy method is to immediately kick down the door, send in the SWAT team, and clear the building. 2:14 Which represents the immediate surgery or radiation. 2:17 Trevor Burrus, Jr. 2:17 Right. 2:17 But the problem is kicking down the door invariably causes permanent collateral damage to the building itself. 2:23 Active surveillance is the alternative. 2:26 You do not kick down the door. 2:28 You hold your position. 2:29 Yes. 2:30 Instead, you set up a highly coordinated 24-7 stakeout. 2:34 You park a surveillance van across the street, you watch every single move the suspect makes, you gather meticulous intelligence, and you only authorize a raid if the suspect actually tries to do something harmful. 2:46 Aaron Ross Powell The Stakeout concept captures the dynamic perfectly because it emphasizes discipline over destruction. 2:53 Active surveillance is a rigorous, calculated monitoring plan designed specifically for low-risk localized prostate cancer. 3:00 Aaron Powell So the medical care team acts as the detectives in the van. 3:04 Exactly. 3:05 They are tracking chemical markers in your blood, conducting physical exams, and uh ordering follow-up internal biopsies. 3:12 They're constantly updating the intelligence dossier on this tumor. 3:16 Aaron Powell And definitive treatment is only initiated if those intelligence reports show a dangerous change in the suspect's behavior. 3:23 But you know, when a doctor says, let's just watch it, it sounds terrifying, like they are doing nothing. 3:29 How do you convince a patient that this stakeout is actually a highly proactive defense? 3:34 Aaron Powell You really have to walk them through the rigor of the schedule. 3:38 Doing nothing implies ignoring the problem and hoping it miraculously goes away, but this is intensely proactive. 3:44 The National Cancer Institute officially recognizes active surveillance as a standard of care option for this specific disease profile. 3:52 Because you're constantly checking for microscopic signs, right? 3:55 Right. 3:56 Because the oncologist is continuously checking to see if the prostate cancer is growing or mutating, they retain the full ability to act decisively before any physical symptoms ever appear in the patient. 4:07 Aaron Ross Powell So you aren't losing the window to cure it. 4:10 Not at all. 4:11 And the most compelling argument we have for patients sitting in that office is the historical data. 4:17 The majority of individuals who undergo this intense monitoring never end up needing the surgery or radiation at all. 4:23 The suspect simply never makes a move. 4:26 Exactly. 4:27 And the patient lives out their natural life without ever suffering the consequences of a SWAT raid. 4:32 Now, since this pathway involves intentionally leaving a known diagnosed cancer inside the body, the vetting process has to be incredibly strict. 4:42 Not everyone gets cleared to be a part of this operation. 4:45 Who actually gets the stakeout assignment? 4:48 The clinical criteria are absolute, and a patient must meet all of them. 4:52 First, the cancer must be strictly localized. 4:55 Meaning the tumor is entirely confined within the capsule of the prostate gland itself. 5:00 Yes, it cannot have spread to nearby tissues, seminal vesicles, or lymph nodes. 5:04 The suspect cannot have left the building. 5:08 Second, the patient must be completely asymptomatic. 5:11 So the tumor cannot be causing any physical issues like bone pain or severe urinary blockages. 5:17 Aaron Powell Correct. 5:18 If it's causing symptoms, it's already behaving aggressively. 5:22 Third is the pathology of the tumor itself, specifically the gliesen grade. 5:26 Aaron Powell From my reading, the Gleason grading system evaluates how the cancer cells look under a microscope compared to normal, healthy prostate cells. 5:34 Aaron Powell That's right. 5:35 Normal cells are highly organized and specialized. 5:38 When cells become cancerous, they lose that organization. 5:42 They kind of forget what the R is supposed to be. 5:44 Aaron Ross Powell So a low or favorable grade means the cells still look largely normal. 5:49 Yes. 5:49 A low gliesen score indicates that the cells are well differentiated. 5:53 Because of this, their biological behavior is indolent. 5:56 They are slow moving and non-aggressive. 5:58 Aaron Powell Okay, so that's localized, asymptomatic, and low grade. 6:02 What's the fourth pillar? 6:03 Aaron Ross Powell The fourth pillar is the patient's PSA level, or prostate-specific antigen. 6:08 The prostate gland naturally produces this protein, but cancer cells tend to leak excess amounts of it into the bloodstream. 6:14 Aaron Powell And looking at the guidelines, the magic number seems to be a PSA under 10 nanograms per milliliter. 6:21 I assume keeping it under that threshold is a strong indicator that the sheer physical volume of the disease is very small. 6:27 Aaron Powell Yes. 6:28 The PSA under 10 is our proxy for tumor mass. 6:31 So a low PSA combined with a low gliesen score and a localized tumor gives the oncologist a highly accurate profile of a sleepy, non-threatening disease. 6:41 But there is a final overarching requirement here, isn't there? 6:45 Aaron Powell There is. 6:46 The patient needs to have a life expectancy of 10 years or more. 6:49 Aaron Powell Why is the 10-year life expectancy mark so critical here? 6:53 Is it because these specific tumors move so slowly that they are unlikely to cause harm within a decade? 6:58 Aaron Powell It comes down to the concept of competing mortality, yes. 7:02 Low-risk prostate cancer is so slow growing that if a man has a life expectancy of fewer than 10 years, maybe due to age or cardiovascular issues, the prostate cancer will almost certainly never be the thing that threatens his life. 7:16 He would just fall into a different care category entirely. 7:19 Exactly. 7:20 But if a man is expected to live 10, 20, or 30 more years, well, the prostate cancer has a very long runway to potentially mutate and become aggressive. 7:30 So the goal of active surveillance for this man is to safely manage the disease over that long horizon without subjecting him to immediate permanent side effects. 7:39 Aaron Powell Precisely. 7:40 The strict criteria work together to statistically guarantee that the cancer will not metastasize while we watch it. 7:48 Okay, let us say I meet all the criteria. 7:50 I have a localized, low-grade tumor, my PSA is a six, I am asymptomatic, and I plan on living for another three decades. 7:59 I am cleared for the stakeout, and I am choosing to leave the cancer in my body. 8:03 Aaron Powell You're officially on the pathway. 8:05 Naturally, I want to know exactly how good your surveillance equipment is. 8:08 What does this intel gathering look like on a practical appointment-by-appointment basis for a patient? 8:14 Aaron Powell The schedule is regimented and deliberately front-loaded. 8:17 We want to establish a baseline of trust early. 8:20 Initially, the care team will schedule tests every three to six months. 8:24 Every three to six months? 8:26 That's frequent. 8:27 It is. 8:28 If the results remain perfectly stable over time, those visits can eventually be spaced further apart, perhaps annually, but the diligence never stops. 8:36 Aaron Powell And what actually happens at these appointments? 8:39 The routine involves regular PSA blood tests to track the chemical levels. 8:43 It also includes manual checks via digital rectal exams to physically feel the surface of the prostate gland for any new nodules or hardening. 8:51 Aaron Powell I have to point out the irony here. 8:53 When we talk about a detective stakeout, we picture high-tech gadgets and dramatic surveillance fans, but the reality of active surveillance involves frequent blood draws and uh invasive physical exams. 9:05 Aaron Powell It is decidedly less glamorous. 9:07 I agree. 9:08 And it doesn't stop there. 9:10 The protocol requires follow-up prostate biopsies, typically scheduled within one to three years after the initial diagnosis. 9:16 Aaron Powell So you're going back in? 9:18 Yes. 9:18 The biopsy is our direct visual confirmation. 9:22 We are sending an agent back into the building to pull tissue samples from the suspect to see if their internal profile has changed. 9:29 And what if it has? 9:30 What if the blood work or the physical exam suggests that the cancer might be waking up? 9:35 Then the team will immediately escalate to advanced imaging. 9:38 We use multiparametric MRI scans to get a highly detailed three-dimensional picture of the prostate. 9:44 Which acts like a window right into the building to see exactly where the suspicious areas are without constantly relying on invasive tissue sampling. 9:52 Historically, doctors were flying blind between biopsies. 9:56 Today the MRI gives us an incredible level of detail. 9:59 Now the oncologists are looking for very specific tripwires. 10:02 If a tripwire is crossed, the stakeout ends. 10:05 You drop the surveillance and you transition to active treatment. 10:08 Looking at the clinical parameters, the doctors aren't just looking at a single high PSA number, are they? 10:14 No, we are analyzing the PSA velocity. 10:16 Velocity. 10:17 So how fast it's moving. 10:19 Exactly. 10:19 Oncologists act like statisticians, evaluating the slope of a curve. 10:24 If your PSA is five, then six months later it is five point two, and six months after that it is five point four. 10:31 That is a gentle slope. 10:33 That is stable. 10:34 But if it jumps from a five to eight to fourteen in a short window. 10:38 The velocity is spiked. 10:40 That is a tripwire. 10:41 Other tripwires include a follow-up biopsy revealing that the cancer has mutated into a higher gliesen grade. 10:47 Or the MRI showing the tumor volume has significantly expanded. 10:51 Or the sudden emergence of new physical symptoms. 10:54 And if any of those occur, the medical team knows the suspect is mobilizing. 10:59 And they pivot immediately to curative treatment like surgery or radiation. 11:03 Aaron Powell Looking at the schedule, I mean the sheer physical intensity of it is surprising. 11:08 Frequent blood draws, invasive physical agrams, follow-up biopsies, MRI machines, it sounds exhausting. 11:16 Aaron Powell It is a massive commitment. 11:18 It forces a very serious conversation about the trade-offs. 11:21 Why on earth would someone choose this relentless lifelong monitoring over just going in tomorrow, doing the surgery, getting the cancer removed, and being done with it? 11:32 The primary motivation, and it is a powerful one, is the absolute protection of the patient's normal quality of life. 11:39 Eradicating prostate cancer is not without profound physical consequences. 11:43 Because the prostate gland sits in a very delicate, anatomical neighborhood. 11:48 Exactly. 11:48 It is surrounded by the nerves and blood vessels that control erectile function. 11:52 And it sits directly beneath the bladder, wrapping around the urethra. 11:56 Surgery and radiation carry significant, sometimes unavoidable risks of damaging those surrounding structures. 12:03 So the collateral damage of kicking down the door is severe. 12:06 We are talking about urinary incontinence and erectile dysfunction. 12:10 Those are the two most prominent life-altering side effects of curative treatment. 12:14 By opting for active surveillance, a man can delay these side effects for years, preserving his physical baseline. 12:20 And in many cases, he avoids them completely for his entire life. 12:24 Yes, because the cancer never progresses. 12:26 He maintains his normal daily routine, his ability to work without the interruption of major surgery, and his intimate relationships. 12:33 He preserves his functional anatomy. 12:36 You are preserving your physical baseline, but I have to play devil's advocate here. 12:40 The trade-off is the mental weight. 12:42 You are carrying the heavy psychological burden of knowing you have cancer. 12:46 It's a very real burden. 12:48 The emotional toll of knowing a tumor is inside your body and then sitting in a waiting room every six months waiting for the next scan is a legitimate, tangible side effect. 12:57 The literature calls it skanxiety. 12:59 Is managing the anxiety of the stakeout sometimes harder than managing the physical disease itself? 13:05 For a distinct subset of men, the psychological burden is absolutely the most challenging aspect of the entire pathway. 13:11 Skangxiety is the intense, sometimes paralyzing dread that builds up in the weeks and days before the next PSA test or biopsy results. 13:20 You're asking a patient to live peacefully with a known internal threat. 13:25 Even with the clinical reassurance that the tumor is low risk, there is always that small, nagging voice asking, what if it grew since the last test? 13:34 The frequent appointments serve as a constant, inescapable reminder of their mortality. 13:39 It requires a massive amount of psychological resilience to trust the clinical data over your own survival instinct to panic. 13:46 I imagine there are patients who physically qualify perfectly for active surveillance, but who eventually demand the surgery anyway simply because they cannot sleep at night. 13:54 It happens. 13:55 Sometimes a patient will willingly accept the risks of incontinence and erectile dysfunction just to achieve the peace of mind that the cancer is physically gone. 14:04 It is a highly personal calculation. 14:07 You are trading potential physical trauma for guaranteed psychological endurance. 14:12 That's a very fair way to put it. 14:14 And because the stakes of this decision are so incredibly high, we must clearly differentiate this rigorous approach from another term listeners might encounter in medical literature, which is watchful waiting. 14:25 Looking at the terminology, it is easy to see how people confuse the two. 14:29 Both involve not immediately treating the cancer. 14:31 But watchful waiting seems to operate on a completely different philosophy. 14:35 Aaron Powell A vastly different philosophy. 14:37 If active surveillance is about perfectly timing a cure, is watchful waiting essentially what doctors do when they have given up on curing the patient? 14:45 Aaron Powell It is not about giving up. 14:47 It is about shifting the medical objective based on the patient's reality. 14:51 Watchful waiting is a strategy generally reserved for older men or patients who have a much shorter life expectancy due to other severe compounding health issues. 15:00 Aaron Powell Like advanced heart disease or severe pulmonary conditions. 15:03 Aaron Powell Exactly. 15:04 In watchful waiting, the medical team makes a conscious decision that they are not going to try to cure the prostate cancer because the patient will likely pass away from their other conditions long before the prostate cancer becomes lethal. 15:16 Aaron Powell So the intel gathering is entirely different. 15:19 You aren't doing the intense schedule of biopsies and MRIs. 15:22 Aaron Powell Precisely. 15:23 Watchful waiting checks for physical symptoms far less frequently. 15:27 We do not do follow-up biopsies. 15:29 If the cancer eventually grows and begins to cause physical discomfort, the treatment administered is palliative, not curative. 15:35 Aaron Ross Powell So the goal is simply to ease the pain, manage the urinary symptoms, and maintain comfort. 15:41 Right. 15:41 Active surveillance, conversely, is a pathway with strict curative intent. 15:46 The entire purpose of the frequent PSA checks and the MRIs is to catch microscopic changes early enough so that a definitive curative treatment can still be successfully administered if needed. 15:56 Aaron Powell So watchful waiting is about prioritizing comfort, while active surveillance is about perfectly timing a cure. 16:02 Trevor Burrus That is the crucial distinction. 16:04 Aaron Ross Powell, which highlights why you cannot manage active surveillance with a casual visit to your primary care doctor. 16:09 It requires an oncologist acting as a master analyst. 16:13 They are comparing the initial tissue architecture against the follow-up biopsy to track cellular evolution. 16:19 They are running continuous risk assessments. 16:21 It is the ultimate embodiment of modern personalized medicine. 16:25 The data analysis is intricate and highly tailored to the individual. 16:29 We are no longer applying a blunt, destructive instrument to every single case that comes through the door. 16:34 We are tailoring the approach to the specific biology of the patient's tumor and their specific life circumstances. 16:40 Aaron Powell It requires immense trust between the patient and the care team, and it requires a steadfast commitment to the monitoring process. 16:47 But the dividend for that patient's years or even decades of preserved physical function is incalculable. 16:55 It really reframes the very concept of health care. 16:57 The observation itself is the treatment. 17:00 To synthesize everything we have unpacked today, active surveillance is a safe, established, and rigorous standard of care. 17:07 It is exclusively for men with localized, low-risk prostate cancer who meet strict clinical criteria. 17:13 Aaron Powell Criteria like a low gliasing grade, a PSA under 10, and being asymptomatic. 17:19 Aaron Powell Yes, and it involves a relentless schedule of blood tests, physical exams, and advanced imaging. 17:25 The primary goal is to protect a man's quality of life, completely sparing him from life-altering side effects like urinary incontinence and erectile dysfunction. 17:35 All without sacrificing the medical team's ability to completely cure the disease if the tumor ever decides to wake up. 17:41 It is a profound exercise in medical patients. 17:45 Which brings us to a final thought to leave you with, something beyond the current guidelines. 17:50 What does it mean for the future of medicine when our absolute greatest weapon against a disease as terrifying as cancer isn't always a scalpel and it isn't always a radiation beam, but simply the patience and the technology to observe? 18:04 It's a paradigm shift. 18:05 It really is. 18:06 As imaging technology and artificial intelligence continue to evolve at an exponential rate, analyzing PSA velocity and MRI scans with superhuman precision, could the stakeout eventually become completely invisible? 18:19 Imagine a near future where constant, non-invasive, AI-driven monitoring removes the need for physical biopsies entirely and removes the dreaded scansiety along with it. 18:31 A future where cancer is turned from an acute, terrifying crisis into a quietly managed background process on your smartphone. 18:38 That is something fascinating to ponder. 18:41 Thank you for joining us on this deep dive. 18:43 We will catch you on the next one.
Community discussion